FFA
MPLT

Farther Finance Advisors’s MapLight Therapeutics MPLT Stock Holding History

Farther Finance Advisors’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3K Hold
120
– – ﹤0.01% 4873
2026
Q1 		$2.5K Hold
120
– – ﹤0.01% 4813
2025
Q4 		$2.11K Buy
+120
New +$2.01K ﹤0.01% 4676

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Farther Finance Advisors's MPLT Position: Q2 2026 in Review

Farther Finance Advisors held its MapLight Therapeutics (MPLT) position steady in Q2 2026 at 120 shares worth $4.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4873.

Farther Finance Advisors first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Farther Finance Advisors held 120 shares of MapLight Therapeutics worth $4.3K as of Q2 2026.
  • Farther Finance Advisors left its MapLight Therapeutics share count unchanged in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4873 holding.
  • Farther Finance Advisors first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.